Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.41 |
| ▸ | CTSB | P07858 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 8/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.39 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.39 |
| ▸ | PLIN1 | O60240 | 1/20 | 0.39 |
| ▸ | CACNA1F | O60840 | 1/20 | 0.39 |
| ▸ | GMNN | O75496 | 1/20 | 0.39 |
| ▸ | KCNK2 | O95069 | 1/20 | 0.39 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.39 |
| ▸ | GSR | P00390 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3520078 | 0.87 | TDP1 (0.40) | ALDH1A1CYP3A4MAPTSMN1; SMN2KMT2A | |
| SCHEMBL31381636 | 0.87 | CYP1A2 (0.41) | ALDH1A1CYP3A4MAPTL3MBTL1SMN1; SMN2 | |
| SCHEMBL13277488 | 0.87 | CYP1A2 (0.41) | ALDH1A1CYP3A4MAPTL3MBTL1SMN1; SMN2 | |
| SCHEMBL2624003 | 0.85 | L3MBTL1 (0.42) | ALDH1A1CYP3A4CTSBMAPTL3MBTL1 | |
| SCHEMBL1068541 | 0.84 | MAPT (0.50) | ALDH1A1CYP3A4CTSBMAPTL3MBTL1 | |
| SCHEMBL13317849 | 0.83 | ALDH1A1 (0.45) | ALDH1A1CYP3A4CTSBMAPTL3MBTL1 | |
| SCHEMBL11144125 | 0.82 | ALDH1A1 (0.45) | ALDH1A1CYP3A4CTSBMAPTL3MBTL1 | |
| SCHEMBL31451782 | 0.81 | ALDH1A1 (0.46) | ALDH1A1CYP3A4CTSBMAPTL3MBTL1 | |
| SCHEMBL31451909 | 0.81 | MAPT (0.39) | ALDH1A1CYP3A4MAPTL3MBTL1SMN1; SMN2 | |
| SCHEMBL17375039 | 0.81 | MAPT (0.39) | ALDH1A1CYP3A4MAPTL3MBTL1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8426426-B2 | Gyrase inhibitors and uses thereof | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-04-23 | — | — | US | disclosed |
| US-8426426-B2 | Gyrase inhibitors and uses thereof | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-04-23 | — | — | US | disclosed |
| US-8426426-B2 | Gyrase inhibitors and uses thereof | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-04-23 | — | — | US | disclosed |
| US-20110104207-A1 | GYRASE INHIBITORS AND USES THEREOF | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-05-05 | — | — | US | disclosed |
| US-20110104207-A1 | GYRASE INHIBITORS AND USES THEREOF | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-05-05 | — | — | US | disclosed |
| US-20110104207-A1 | GYRASE INHIBITORS AND USES THEREOF | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-05-05 | — | — | US | disclosed |
| US-7727992-B2 | Gyrase inhibitors and uses thereof | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-06-01 | — | — | US | disclosed |
| US-7727992-B2 | Gyrase inhibitors and uses thereof | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-06-01 | — | — | US | disclosed |
| US-7727992-B2 | Gyrase inhibitors and uses thereof | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-06-01 | — | — | US | disclosed |
| US-20100105701-A1 | GYRASE INHIBITORS AND USES THEREOF | VERTEX PHARMACEUTICALS INCORPORATED | 2010-04-29 | — | — | US | disclosed |
| US-20100105701-A1 | GYRASE INHIBITORS AND USES THEREOF | VERTEX PHARMACEUTICALS INCORPORATED | 2010-04-29 | — | — | US | disclosed |
| US-20100105701-A1 | GYRASE INHIBITORS AND USES THEREOF | VERTEX PHARMACEUTICALS INCORPORATED | 2010-04-29 | — | — | US | disclosed |
| EP-1511482-B1 | 2-UREIDO-6-HETEROARYL-3H-BENZOIMIDAZOLE-4-CARBOXYLIC ACID DERIVATIVES AND RELATED COMPOUNDS AS GYRASE AND/OR TOPOISOMERASE IV INHIBITORS FOR THE TREATMENT OF BACTERIAL INFECTIONS | VERTEX PHARMA (US) | 2006-11-15 | — | — | EP | disclosed |
| EP-1511482-A1 | 2-UREIDO-6-HETEROARYL-3H-BENZOIMIDAZOLE-4-CARBOXYLIC ACID DERIVATIVES AND RELATED COMPOUNDS AS GYRASE AND/OR TOPOISOMERASE IV INHIBITORS FOR THE TREATMENT OF BACTERIAL INFECTIONS | Vertex Pharmaceuticals Incorporated (US) | 2005-03-09 | — | — | EP | disclosed |
| WO-2003105846-A1 | 2-UREIDO-6-HETEROARYL-3H-BENZOIMIDAZOLE-4-CARBOXYLIC ACID DERIVATIVES AND RELATED COMPOUNDS AS GYRASE AND/OR TOPOISOMERASE IV INHIBITORS FOR THE TREATMENT OF BACTERIAL INFECTIONS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2003-12-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100105701-A1 | GYRASE INHIBITORS AND USES THEREOF | GMPS, NQO2, TOP1 | ALDH1A1 2583/4885CYP3A4 1231/4885CTSB 815/4885 |
| US-20110104207-A1 | GYRASE INHIBITORS AND USES THEREOF | GMPS, NQO2, TOP1 | ALDH1A1 2583/4885CYP3A4 1231/4885CTSB 815/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.